<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35203563</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2227-9059</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Biomedicines</Title>
          <ISOAbbreviation>Biomedicines</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Misuse of Anticholinergic Medications: A Systematic Review.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">355</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines10020355</ELocationID>
        <Abstract>
          <AbstractText>(1) Background: Over the last decade, misuse and diversion of medications has appeared to be increasingly concerning phenomena, including a range of different molecules. As current knowledge on the abuse of centrally acting anticholinergics is limited, the aim of the present study is to review the relevant published data, focusing on the following molecules: benztropine, biperiden, scopolamine, orphenadrine, and benzhexol/trihexyphenidyl (THP). (2) Methods: A systematic literature review was carried out using Pubmed, Scopus, and Web of Science databases following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Research methods were registered on PROSPERO (CRD42021257293). (3) Results: A total of 48 articles, including case reports, surveys, and retrospective case series analyses, were included. Most articles focused on benzhexol/THP (<i>n</i> = 25), and benztropine (<i>n</i> = 4). The routes of administration were mostly oral, and macrodoses together concomitant illicit drugs, e.g., cocaine, have been recorded. Toxidromes included both physical (e.g., tachycardia, tachypnoea, dilatated pupils, dry skin, urinary retention, ataxia, etc.) and psychiatric symptoms (e.g., anxiety, agitation, delirium, etc.). Fatal outcomes were very rare but reported. (4) Conclusion: Results from the present study show that anticholinergic misusing issues are both widespread worldwide and popular. Considering the potential adverse effects associated, healthcare professionals should be vigilant and monitor eventual misusing issues.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Chiappini</LastName>
            <ForeName>Stefania</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0002-6810-1540</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, 66100 Chieti, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mosca</LastName>
            <ForeName>Alessio</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-3832-1398</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, 66100 Chieti, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miuli</LastName>
            <ForeName>Andrea</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-2431-0460</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, 66100 Chieti, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Semeraro</LastName>
            <ForeName>Francesco Maria</ForeName>
            <Initials>FM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, 66100 Chieti, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mancusi</LastName>
            <ForeName>Gianluca</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, 66100 Chieti, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Santovito</LastName>
            <ForeName>Maria Chiara</ForeName>
            <Initials>MC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, 66100 Chieti, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Di Carlo</LastName>
            <ForeName>Francesco</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0001-8058-3426</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, 66100 Chieti, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pettorruso</LastName>
            <ForeName>Mauro</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0002-4164-3040</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, 66100 Chieti, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guirguis</LastName>
            <ForeName>Amira</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-8255-0660</Identifier>
            <AffiliationInfo>
              <Affiliation>Medical School, The Grove, Swansea University, Swansea SA2 8PP, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Corkery</LastName>
            <ForeName>John Martin</ForeName>
            <Initials>JM</Initials>
            <Identifier Source="ORCID">0000-0002-3849-817X</Identifier>
            <AffiliationInfo>
              <Affiliation>Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Martinotti</LastName>
            <ForeName>Giovanni</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-7292-2341</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, 66100 Chieti, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schifano</LastName>
            <ForeName>Fabrizio</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield AL10 9AB, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Di Giannantonio</LastName>
            <ForeName>Massimo</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, 66100 Chieti, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Biomedicines</MedlineTA>
        <NlmUniqueID>101691304</NlmUniqueID>
        <ISSNLinking>2227-9059</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">anticholinergic drugs</Keyword>
        <Keyword MajorTopicYN="N">drug abuse</Keyword>
        <Keyword MajorTopicYN="N">drug diversion</Keyword>
        <Keyword MajorTopicYN="N">drug misuse</Keyword>
      </KeywordList>
      <CoiStatement>F.S. was a member of the UK Advisory Council on the Misuse of Drugs (ACMD; 2011–2019) and is currently a member of the EMA Advisory Board (Psychiatry). J.C. is a member of the ACMD’s Novel Psychoactive Substances and Technical Committees. G.M. has been a consultant and a speaker and has received research grants from Angelini, Doc Generici, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Servier, and Recordati. S.C., A.M. (Alessio Mosca), F.D.C., G.M., M.P., A.Mi. (Andrea Miuli), A.G., and F.S. (Francesco Semeraro) have nothing to declare. M.D.G. has been a consultant and a speaker and has received research grants from Angelini, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Servier, and Recordati.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
          <Hour>1</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35203563</ArticleId>
        <ArticleId IdType="pmc">PMC8962297</ArticleId>
        <ArticleId IdType="doi">10.3390/biomedicines10020355</ArticleId>
        <ArticleId IdType="pii">biomedicines10020355</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Chiappini S., Guirguis A., Corkery J.M., Schifano F. Misuse of prescription and over-the-counter drugs to obtain illicit highs: How pharmacists can prevent abuse. Pharm. J. 2020;305:1–31.</Citation>
        </Reference>
        <Reference>
          <Citation>European Monitoring Centre for Drugs and Drug Addiction  Non-Medical Use of Medicines: Health and Social Responses [Internet] 2021.  [(accessed on 24 December 2021)].  Available online:  https://www.emcdda.europa.eu/publications/mini-guides/non-medical-use-of-medicines-health-and-social-responses_en.</Citation>
        </Reference>
        <Reference>
          <Citation>Caplan J.P., Epstein L.A., Quinn D.K., Stevens J.R., Stern T.A. Neuropsychiatric effects of prescription drug abuse. Neuropsychol. Rev. 2007;17:363–380. doi: 10.1007/s11065-007-9037-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11065-007-9037-7</ArticleId>
            <ArticleId IdType="pubmed">17701457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buhrich N., Weller A., Kevans P. Misuse of anticholinergic drugs by people with serious mental illness. Psychiatr. Serv. 2000;51:928–929. doi: 10.1176/appi.ps.51.7.928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/appi.ps.51.7.928</ArticleId>
            <ArticleId IdType="pubmed">10875961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zemishlany Z., Aizenberg D., Weiner Z., Weizman A. Trihexyphenidyl (Artane) abuse in schizophrenic patients. Int. Clin. Psychopharmacol. 1996;11:199–202. doi: 10.1097/00004850-199609000-00007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004850-199609000-00007</ArticleId>
            <ArticleId IdType="pubmed">8923099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gjerden P., Bramness J.G., Slørdal L. The use and potential abuse of anticholinergic antiparkinson drugs in Norway: A pharmacoepidemiological study. Br. J. Clin. Pharmacol. 2009;67:228–233. doi: 10.1111/j.1365-2125.2008.03342.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2125.2008.03342.x</ArticleId>
            <ArticleId IdType="pmc">PMC2670380</ArticleId>
            <ArticleId IdType="pubmed">19094158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pullen G.P., Best N.R., Maguire J. Anticholinergic abuse: A common problem? Br. Med. J. 1984;289:612–613. doi: 10.1136/bmj.289.6445.612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.289.6445.612</ArticleId>
            <ArticleId IdType="pmc">PMC1442870</ArticleId>
            <ArticleId IdType="pubmed">6432211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Christensen R.C. Screening for anticholinergic abuse in patients with chronic mental illness. Am. J. Emerg. Med. 2003;21:508. doi: 10.1016/S0735-6757(03)00167-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0735-6757(03)00167-0</ArticleId>
            <ArticleId IdType="pubmed">14574665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., et al.  The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.n71</ArticleId>
            <ArticleId IdType="pmc">PMC8005924</ArticleId>
            <ArticleId IdType="pubmed">33782057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moher D., Shamseer L., Clarke M., Ghersi D., Liberati A., Petticrew M., Shekelle P., Stewart L.A., PRISMA-P Group  Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 2015;4:1. doi: 10.1186/2046-4053-4-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2046-4053-4-1</ArticleId>
            <ArticleId IdType="pmc">PMC4320440</ArticleId>
            <ArticleId IdType="pubmed">25554246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bernardo W.M. PRISMA Statement and PROSPERO.  [(accessed on 24 December 2021)];Int. Braz. J. Urol. 2017 43:383–384. doi: 10.1590/s1677-5538.ibju.2017.03.02. Available online:  http://www.intbrazjurol.com.br/pdf/vol43n01/vol43n01_2017.pdf.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/s1677-5538.ibju.2017.03.02</ArticleId>
            <ArticleId IdType="pmc">PMC5462126</ArticleId>
            <ArticleId IdType="pubmed">28520335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goggin D.A., Solomon G.F. Trihexyphenidyl abuse for euphorigenic effect. Am. J. Psychiatry. 1979;36:459–460. doi: 10.1176/ajp.1979.136.4a.459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/ajp.1979.136.4a.459</ArticleId>
            <ArticleId IdType="pubmed">426119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison G. The abuse of anticholinergic drugs in adolescents. Br. J. Psychiatry. 1980;137:495. doi: 10.1192/bjp.137.5.495a.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1192/bjp.137.5.495a</ArticleId>
            <ArticleId IdType="pubmed">7470774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohandas E., Kothari V.C., Vanvaria S.K., Mambwe C.C., Haworth A. Trihexyphenidyl abuse. East Afr. Med. J. 1987;64:156–157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3622344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deutsch A., Eyma J. Massive ingestion of Trihexyphenidyl. Am. J. Psychiatry. 1992;149:574–575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1554053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kajimura N., Mizuki Y., Kai S., Suetsugi M., Yamada M., Okuma T. Memory and cognitive impairments in a case of long-term trihexyphenidyl abuse. Pharmacopsychiatry. 1993;26:59–62. doi: 10.1055/s-2007-1014343.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-2007-1014343</ArticleId>
            <ArticleId IdType="pubmed">8378414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaminer Y., Munitz H., Wijsenbeek H. Trihexyphenidyl (artane) abuse: Euphoriant and anxiolytic. Br. J. Psychiatry. 1982;140:473–474. doi: 10.1192/bjp.140.5.473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1192/bjp.140.5.473</ArticleId>
            <ArticleId IdType="pubmed">6125226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keshavan M.S., Burton S., Murphy M., Checkley S.A., Crammer J.L. Benzexhol withdrawal and Cholinergic Mechanisms in Depression. Br. J. Psychiatry. 1985;147:560–564. doi: 10.1192/bjp.147.5.560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1192/bjp.147.5.560</ArticleId>
            <ArticleId IdType="pubmed">4075054</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lo Y., Tsai S.J. Trihexyphenidyl abuse in schizophrenic patient: A case report. Chin. Med. J. 1996;57:157–160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8634932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Macvicar K. Abuse of antiparkinsonian drugs by psychiatric patients. Am. J. Psychiatry. 1977;134:809–811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">869063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petković S., Durendić-Brenesel M., Dolai M., Samojlik I. Fatal Intoxication Because of Trihexyphenidyl. J. Forensic. Sci. 2011;56:1383–1386. doi: 10.1111/j.1556-4029.2011.01816.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1556-4029.2011.01816.x</ArticleId>
            <ArticleId IdType="pubmed">21644988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rao M.G., Varambally S., Raveendranathan D., Venkatasubramanian G., Gangadhar B.N. Trihexyphenidyl use and dependence: A case report. Ment. Health Subst. Use. 2014;7:258–262. doi: 10.1080/17523281.2013.852130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/17523281.2013.852130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sofair J., Campion J., Angrist B. High dose trihexyphenidyl abuse with psychological dependence. J. Clin. Psychopharmacol. 1983;3:263–264. doi: 10.1097/00004714-198308000-00033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004714-198308000-00033</ArticleId>
            <ArticleId IdType="pubmed">6886042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fisch R.Z. Trihexyphenidyl abuse: Therapeutic implications for negative symptoms of schizophrenia? Acta Psychiatr. Scand. 1987;75:91–94. doi: 10.1111/j.1600-0447.1987.tb02757.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0447.1987.tb02757.x</ArticleId>
            <ArticleId IdType="pubmed">3577845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McInnis M., Petursson H. Trihexyphenidyl dependence. Acta Psychiatr. Scand. 1984;69:538–542. doi: 10.1111/j.1600-0447.1984.tb02528.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0447.1984.tb02528.x</ArticleId>
            <ArticleId IdType="pubmed">6741602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michael A., Murali T., Mathai P.J., Gopinath P.S. Trihexylphenidyl dependence—Report of two cases. Indian J. Psychiatry. 1984;26:178–179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3012227</ArticleId>
            <ArticleId IdType="pubmed">21965980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thunyapipat C., Manaboriboon B., In-iw S., Kriengsoontornkij W. A Case Series of Trihexyphenidyl Abuse for Recreational Purpose in Thai Children and Adolescents. J. Adolesc. Health. 2018;62:S137. doi: 10.1016/j.jadohealth.2017.11.280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jadohealth.2017.11.280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubinstein J.S. Antiparkinsonian drug abuse: Eight case reports. Hosp. Community Psychiatry. 1979;30:34–37. doi: 10.1176/ps.30.1.34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1176/ps.30.1.34</ArticleId>
            <ArticleId IdType="pubmed">758251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahal P., Nishanth K.N., Mahapatra A., Sarkar S., Balhara Y.P.S. Trihexyphenidyl Misuse in Delusional Disorder. J. Neurosci. Rural Pract. 2018;9:428–430. doi: 10.4103/jnrp.jnrp_569_17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/jnrp.jnrp_569_17</ArticleId>
            <ArticleId IdType="pmc">PMC6050776</ArticleId>
            <ArticleId IdType="pubmed">30069107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Younis A.A., Moselhy H.F. Benzhexol-Dependence resulting from self-medication for intermittent explosive disorder. Int. J. Psychiatry Clin. Pract. 2009;13:11–15. doi: 10.1080/13651500802192421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/13651500802192421</ArticleId>
            <ArticleId IdType="pubmed">24946116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crawshaw J.A., Mullen P.E. A study of benzhexol abuse. Br. J. Psychiatry. 1984;145:300–303. doi: 10.1192/bjp.145.3.300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1192/bjp.145.3.300</ArticleId>
            <ArticleId IdType="pubmed">6478124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qureshi N.A. Trihexyphenidyl (Artane) Abuse among Saudi Psychiatric Patients. Ann. Saudi Med. 1992;12:391–394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17587000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qureshi N.A., Abdelgadir M.H., El-haraka E.A. Trihexyphenidyl (Artane) Dependence: A Controlled. Ann. Saudi Med. 1997;17:185–190. doi: 10.5144/0256-4947.1997.185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5144/0256-4947.1997.185</ArticleId>
            <ArticleId IdType="pubmed">17377427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torrents R., Ferré J.F., Konareff A., Hemery P., Sherwin K., Lassalle C., Nicolas S., Sami S. Misuse of Trihexyphenidyl (Artane) on Réunion Island. J. Clin. Psychopharmacol. 2018;38:250–253. doi: 10.1097/JCP.0000000000000882.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JCP.0000000000000882</ArticleId>
            <ArticleId IdType="pubmed">29620695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nappo S.A., De Oliveira L.G., Van Der Meer Sanchez Z., De Araújo Carlini E. Trihexyphenidyl (Artane®): A Brazilian study of its abuse. Subst. Use Misuse. 2005;40:473–482. doi: 10.1081/JA-200052423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1081/JA-200052423</ArticleId>
            <ArticleId IdType="pubmed">15830730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Craig D.H., Rosen P. Abuse of antiparkinsonian drugs. Ann. Emerg. Med. 1981;10:98–100. doi: 10.1016/S0196-0644(81)80347-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0196-0644(81)80347-2</ArticleId>
            <ArticleId IdType="pubmed">7224257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esang M., Person U.S., Izekor O.O., Le T.K., Ahmadian D. An Unlikely Case of Benztropine Misuse in an Elderly Schizophrenic. Cureus. 2021;13:2–5. doi: 10.7759/cureus.13434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7759/cureus.13434</ArticleId>
            <ArticleId IdType="pmc">PMC7978387</ArticleId>
            <ArticleId IdType="pubmed">33758719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Isbister G.K., Oakley P., Whyte I., Dawson A. Treatment of anticholinergic-induced ileus with neostigmine. Ann. Emerg. Med. 2001;38:689–693. doi: 10.1067/mem.2001.119458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1067/mem.2001.119458</ArticleId>
            <ArticleId IdType="pubmed">11719751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taylor C.L., Taylor S.F. Atropine Autoinjector Use as a Suicidal Gesture. J. Emerg. Med. 2008;34:397–400. doi: 10.1016/j.jemermed.2007.05.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jemermed.2007.05.037</ArticleId>
            <ArticleId IdType="pubmed">17931821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H.E. Street Drug Toxicity Resulting from Opiates Combined with Anticholinergics. Prehosp. Emerg. Care. 2002;6:351–354. doi: 10.1080/10903120290938463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/10903120290938463</ArticleId>
            <ArticleId IdType="pubmed">12109584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiner A.L., Bayer M.J., McKay C.A., DeMeo M., Starr E. Anticholinergic poisoning with adulterated intranasal cocaine. Am. J. Emerg. Med. 1998;16:517–520. doi: 10.1016/S0735-6757(98)90007-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0735-6757(98)90007-9</ArticleId>
            <ArticleId IdType="pubmed">9725971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jalali F., Afshari R., Babaei A. Smoking crushed hyoscine/scopolamine tablets as drug abuse. Subst. Use Misuse. 2014;49:793–797. doi: 10.3109/10826084.2014.880178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10826084.2014.880178</ArticleId>
            <ArticleId IdType="pubmed">24494624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kummer S., Rickert A., Daldrup T., Mayatepek E. Abuse of the over-the-counter antispasmodic butylscopolamine for the home synthesis of psychoactive scopolamine. Eur. J. Pediatr. 2016;175:1019–1021. doi: 10.1007/s00431-015-2683-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00431-015-2683-5</ArticleId>
            <ArticleId IdType="pubmed">26691719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strano-Rossi S., Mestria S., Bolino G., Polacco M., Grassi S., Oliva A. Scopolamine fatal outcome in an inmate after buscopan® smoking. Int. J. Legal Med. 2021;135:1455–1460. doi: 10.1007/s00414-021-02583-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00414-021-02583-2</ArticleId>
            <ArticleId IdType="pmc">PMC8062144</ArticleId>
            <ArticleId IdType="pubmed">33890166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Affaticati A., Lidia Gerra M., Amerio A., Inglese M., Antonioni M.C., Marchesi C. The controversial case of biperiden from prescription drug to drug of abuse. J. Clin. Psychopharmacol. 2015;35:749–750. doi: 10.1097/JCP.0000000000000421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/JCP.0000000000000421</ArticleId>
            <ArticleId IdType="pubmed">26479221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozucelik D.N., Yucel N., Coskun S., Cobanoglu M., Kunt M.M. Gluteal abscess following intramuscular injection of dissolved biperiden tablets. Int. J. Clin. Pract. 2007;61:1417–1418. doi: 10.1111/j.1742-1241.2005.00710.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1742-1241.2005.00710.x</ArticleId>
            <ArticleId IdType="pubmed">17627718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sinha S.K., Diman S., Sidana A. A rare case of dicyclomineand mefenamic acid fulfilling criteria of dependence syndrome. Indian J. Psychiatry. 2020;62:740–741. doi: 10.4103/psychiatry.IndianJPsychiatry_562_19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/psychiatry.IndianJPsychiatry_562_19</ArticleId>
            <ArticleId IdType="pmc">PMC8052875</ArticleId>
            <ArticleId IdType="pubmed">33896989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das S., Mondal S., Datta A., Bandyopadhyay S. A rare case of dicyclomine abuse. J. Young Pharm. 2013;5:106–107. doi: 10.1016/j.jyp.2013.08.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jyp.2013.08.004</ArticleId>
            <ArticleId IdType="pmc">PMC3812884</ArticleId>
            <ArticleId IdType="pubmed">24396252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nissen T. Toxic psychosis due to self-administered antiparkinson drug overdosage: A case report. Nord. J. Psychiatry. 1987;41:25–26. doi: 10.3109/08039488709094922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/08039488709094922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schifano F., Marra R., Magni G. Orphenadrine abuse. South Med. J. 1988;81:546. doi: 10.1097/00007611-198804000-00040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00007611-198804000-00040</ArticleId>
            <ArticleId IdType="pubmed">3358186</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bozkurt M., Karabulut V., Evren C., Seker M., Kan H. Intravenous abuse of tropicamide in opioid use disorder: Presentation of 2 cases. Subst. Abus. 2015;36:170–173. doi: 10.1080/08897077.2014.924465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08897077.2014.924465</ArticleId>
            <ArticleId IdType="pubmed">24892477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spagnolo P.A., Badiani A., Nencini P. Polydrug abuse by intravenous use of heroin and tropicamide-containing eyedrops. Clin. Neuropharmacol. 2013;36:100–101. doi: 10.1097/WNF.0b013e31828da20e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WNF.0b013e31828da20e</ArticleId>
            <ArticleId IdType="pubmed">23673915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Michael T., Paul C. A new medication, a new toxidrome—A case report of anticholinergic wipe toxicity due to improper medication use. Am. J. Emerg. Med. 2021;46:797.e1–797.e2. doi: 10.1016/j.ajem.2021.01.060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajem.2021.01.060</ArticleId>
            <ArticleId IdType="pubmed">33583621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balasar M., Çiçekçi F. Oxybutynin addiction amongst prisoners: Two case reports. Anadolu Psikiyatr. Derg. 2016;17:77–79. doi: 10.5455/apd.172823.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.5455/apd.172823</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Al-Khalaileh W., Abu-Farha R., Wazaify M., Van Hout M.C. Ophthalmic drug abuse: An observational study from community pharmacies. Res. Soc. Adm. Pharm. 2019;15:943–948. doi: 10.1016/j.sapharm.2019.01.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.sapharm.2019.01.016</ArticleId>
            <ArticleId IdType="pubmed">30737195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coid J., Strang J. Mania secondary to procyclidine abuse.  [(accessed on 24 December 2021)];Br. J. Psychiatry. 1982 141:81–84. doi: 10.1192/bjp.141.1.81. Available online:  http://www.ncbi.nlm.nih.gov/pubmed/7116076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1192/bjp.141.1.81</ArticleId>
            <ArticleId IdType="pubmed">7116076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wells B., Marken P., Rickman L., Brown C., Hamann G., Grimmig J. Characterizing anticholinergic abuse in community mental health. J. Clin. Psychopharmacol. 1989;9:431–435. doi: 10.1097/00004714-198912000-00009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00004714-198912000-00009</ArticleId>
            <ArticleId IdType="pubmed">2592590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naja W.J., Halaby A. Anticholinergic Use and Misuse in Psychiatry: A Comprehensive and Critical Review. J. Alcohol. Drug Depend. 2017;5:5–8. doi: 10.4172/2329-6488.1000263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4172/2329-6488.1000263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katzung B.G., Vanderah T.W.  Basic &amp; Clinical Pharmacology. 15th ed. McGraw-Hill; New York, NY, USA: 2021.  [(accessed on 24 December 2021)]. Notice. Available online:  http://accesspharmacy.mhmedical.com/content.aspx?aid=1176460635.</Citation>
        </Reference>
        <Reference>
          <Citation>Dose M., Tempel H.D. Abuse potential of anticholinergics. Pharmacopsychiatry. 2000;33:43–46. doi: 10.1055/s-2000-7583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-2000-7583</ArticleId>
            <ArticleId IdType="pubmed">11072764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerretsen P., Pollock B.G. Drugs with anticholinergic properties: A current perspective on use and safety. Expert Opin. Drug Saf. 2011;10:751–765. doi: 10.1517/14740338.2011.579899.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1517/14740338.2011.579899</ArticleId>
            <ArticleId IdType="pubmed">21635190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinotti G., De Risio L., Vannini C., Schifano F., Pettorruso M., Di Giannantonio M. Substance-Related exogenous psychosis: A postmodern syndrome. CNS Spectr. 2021;26:84–91. doi: 10.1017/S1092852920001479.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1092852920001479</ArticleId>
            <ArticleId IdType="pubmed">32580808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubinstein J.S. Abuse of Antiparkinsonism Drugs: Feigning of Extrapyramidal Symptoms to Obtain Trihexyphenidyl. JAMA J. Am. Med. Assoc. 1978;239:2365–2366. doi: 10.1001/jama.239.22.2365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.239.22.2365</ArticleId>
            <ArticleId IdType="pubmed">642176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marken P.A., Stuart Munro J. Selecting a selective serotonin reuptake inhibitor: Clinically important distinguishing features. Prim. Care Companion J. Clin. Psychiatry. 2000;2:205–210. doi: 10.4088/PCC.v02n0602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4088/PCC.v02n0602</ArticleId>
            <ArticleId IdType="pmc">PMC181142</ArticleId>
            <ArticleId IdType="pubmed">15014630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barrett S.P., Meisner J.R., Stewart S.H. What constitutes prescription drug misuse? Problems and pitfalls of current conceptualizations. Curr. Drug Abuse Rev. 2008;1:255–262. doi: 10.2174/1874473710801030255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1874473710801030255</ArticleId>
            <ArticleId IdType="pubmed">19630724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casati A., Sedefov R., Pfeiffer-Gerschel T. Misuse of medicines in the European union: A systematic review of the literature. Eur. Addict. Res. 2012;18:228–245. doi: 10.1159/000337028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000337028</ArticleId>
            <ArticleId IdType="pubmed">22572594</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novak S.P., Håkansson A., Martinez-Raga J., Reimer J., Krotki K., Varughese S. Nonmedical use of prescription drugs in the European Union. BMC Psychiatry. 2016;16:274.  doi: 10.1186/s12888-016-0909-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12888-016-0909-3</ArticleId>
            <ArticleId IdType="pmc">PMC4972971</ArticleId>
            <ArticleId IdType="pubmed">27488186</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
